PDCD1 and metastatic melanoma: These patients were subsequentially treated with FMT from two donors who had been treated with anti-PD-1 monotherapy for metastatic melanoma, and achieved a complete response for at least 1 year, together with re-induction of anti-PD-1 immunotherapy.